February 25, 2008

Back to all media releases

Sandoz Bangladesh introduces new packaging with information in Braille format
 

Dhaka, February 25, 2008 - Sandoz, a division of Novartis (Bangladesh) Limited, has introduced new packaging with information in Braille format for the visually impaired people. This initiative is focused on the visually impaired in order for them to gain or improve independence and self-reliance. Sandoz, has already made available 8 products in the market. The outer package has the product name and the strength of the product written in Braille format.

Braille is the internationally widespread reading and writing system for the blind and partially sighted people. the system was founded in 1825 by Louis Braille (1809 - 1852), who lived in France and himself was blind.

This initiative is part of Corporate Social Responsibility, through which Novartis endeavors to create value for society.

About Novartis  

Novartis is a world leader in offering medicines to protect health, treat diseases and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals (Sandoz). We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high quality and affordable generics (Sandoz), human vaccines and leading self-medication OTC brands. Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 people and operate in over 140 countries around the world.

Novartis has manufacturing and marketing operations in Bangladesh since 1973 in areas of Research, Off Patent Branded Generic (Sandoz) and OTC Pharmaceuticals along with Animal Health.

###

Rasna Hasan

Head of Corporate Affairs and Communication

Novartis (Bangladesh) limited

House 50, Road 2A

Dhanmondi RA

Dhaka 1209

BANGLADESH

+880 2 8615302-8

 rasna.hasan@sandoz.com

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Lucentis

Aclasta

Sebivo

Doloran PRT